Cingulate Inc. is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTx-1301 and CTx-1302 utilize a flexible core tableting technology with target product profile designed to deliver a rapid onset and last the entire active day with a controlled descent of plasma drug level and have favorable tolerability. The Company has initiated Phase 3 clinical trials for CTx-1301, with first patients in the adult dose-optimization study dosed in early 2023. In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage.
Company profile
Ticker
CING
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cingulate Therapeutics LLC • Cingulate Works Inc. ...
IRS number
863825535
CING stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
4 Apr 24
424B4
Prospectus supplement with pricing info
3 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
POS AM
Prospectus update (post-effective amendment)
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
1 Apr 24
8-K
Other Events
18 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm |
Cash burn (monthly) | (no burn) | 650.77 k | 1.99 mm | 1.77 mm | 1.43 mm | 1.39 mm |
Cash used (since last report) | n/a | 4.50 mm | 13.78 mm | 12.22 mm | 9.89 mm | 9.61 mm |
Cash remaining | n/a | -2.51 mm | -11.80 mm | -10.23 mm | -7.91 mm | -7.63 mm |
Runway (months of cash) | n/a | -3.9 | -5.9 | -5.8 | -5.5 | -5.5 |
Institutional ownership, Q4 2023
7.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 20 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 3.59 mm |
Total shares | 365.71 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Peter J. Werth | 325.32 k | $3.20 mm |
Shane J. Schaffer | 40.39 k | $397.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Peter J. Werth | Common Stock | Option exercise | Acquire M | Yes | No | 0.0001 | 694,096 | 69.41 | 1,175,925 |
11 Apr 24 | Peter J. Werth | Common Stock | Option exercise | Acquire M | Yes | No | 0.002 | 341,912 | 683.82 | 481,829 |
11 Apr 24 | Peter J. Werth | Pre-Funded Warrant Common Stock | Option exercise | Dispose M | Yes | No | 0.0001 | 694,096 | 69.41 | 0 |
11 Apr 24 | Peter J. Werth | Pre-Funded Warrant Common Stock | Option exercise | Dispose M | Yes | No | 0.002 | 341,912 | 683.82 | 0 |
29 Mar 24 | Raul R. Silva | Stock Option Common Stock | Grant | Acquire A | No | No | 1.1 | 1,000 | 1.10 k | 1,000 |
29 Mar 24 | Matthew Brams | Stock Option Common Stock | Grant | Acquire A | No | No | 1.1 | 1,000 | 1.10 k | 1,000 |
25 Mar 24 | Peter J. Werth | Pre-Funded Warrant Common Stock | Other | Acquire J | Yes | No | 0.0001 | 7,053 | 0.71 | 694,096 |
4 Mar 24 | Shane J. Schaffer | Stock Option Common Stock | Grant | Acquire A | No | No | 1.18 | 57,323 | 67.64 k | 57,323 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 Feb 24
Peering Into Cingulate's Recent Short Interest
5 Feb 24
S&P 500 Gains Over 1%; Amazon Earnings Top Expectations
2 Feb 24
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
2 Feb 24
12 Health Care Stocks Moving In Friday's Intraday Session
2 Feb 24
Press releases
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
16 Apr 24
Cingulate to Participate in Benzinga All Live Access Event
19 Mar 24
Cingulate to Attend DCAT Week 2024 in New York City
6 Mar 24
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
13 Feb 24
Cingulate Announces Closing of $7.5 Million Public Offering
6 Feb 24